Jump to navigation Jump to search

{{#invoke:Infobox|infobox}}{{#invoke:TemplatePar |check |template=Template:Infobox_drug |all= |opt= pronounce= pronounce_ref= pronounce_comment= ATC_prefix= ATC_suffix= ATC_supplemental= ATCvet= CAS_number_Ref= CAS_number= CAS_supplemental= ChEBI= ChEBI_Ref= ChEMBL_Ref= ChEMBL= ChemSpiderID= ChemSpiderID_Ref= chirality= class= DailyMedID= data_page= DrugBank_Ref= DrugBank= Drugs.com= duration_of_action= INN= INN_EMA= IUPAC_name= IUPHAR_ligand= KEGG_Ref= KEGG= MedlinePlus= NIAID_ChemDB= PDB_ligand= PubChemSubstance= PubChem= StdInChIKey_Ref= StdInChIKey= StdInChI_Ref= StdInChI_comment= StdInChI= UNII_Ref= UNII= Verifiedfields= Watchedfields= addiction_liability= alt2= altL= altR= alt= bioavailability= boiling_high= boiling_notes= boiling_point= captionLR= caption= caption2= charge= chemical_formula= chemical_formula_ref= chemical_formula_comment= class1= class2= class3= class4= class5= component1= component2= component3= component4= component5= density= density_notes= dependency_liability= drug_name= elimination_half-life= engvar= excretion= image2= imageL= imageR= image= Jmol= legal_AU= legal_BR= legal_CA= legal_DE= legal_EU= legal_NZ= legal_UK= legal_UN= legal_US= legal_AU_comment= legal_BR_comment= legal_CA_comment= legal_DE_comment= legal_UK_comment= legal_NZ_comment= legal_US_comment= legal_UN_comment= legal_EU_comment= legal_status= licence_CA= licence_EU= licence_US= license_CA= license_EU= license_US= mab_type= melting_high= melting_notes= melting_point= metabolism= metabolites= molecular_weight= molecular_weight_round= molecular_weight_unit= molecular_weight_ref= molecular_weight_comment= onset= pregnancy_AU= pregnancy_US= pregnancy_AU_comment= pregnancy_US_comment= pregnancy_category= protein_bound= routes_of_administration= SMILES= smiles= solubility= sol_units= source= specific_rotation= synonyms= target= tradename= type= vaccine_type= verifiedrevid= width2= widthL= widthR= width= AAN= BAN= JAN= USAN= source_tissues= target_tissues= receptors= agonists= antagonists= precursor= biosynthesis= gt_target_gene= gt_vector= gt_nucleic_acid_type= gt_editing_method= gt_delivery_method= sec_combustion= Ac=Ag=Al=Am=Ar=As=At=Au=B=Ba=Be=Bh=Bi=Bk=Br=C=Ca=Cd=Ce=Cf=Cl=Cm=Cn=Co=Cr=Cs=Cu= D=Db=Ds=Dy=Er=Es=Eu=F=Fe=Fl=Fm=Fr=Ga=Gd=Ge=H=He=Hf=Hg=Ho=Hs=I=In=Ir=K=Kr=La=Li=Lr=Lu=Lv= Mc=Md=Mg=Mn=Mo=Mt=N=Na=Nb=Nd=Ne=Nh=Ni=No=Np=O=Og=Os=P=Pa=Pb=Pd=Pm=Po=Pr=Pt=Pu=Ra=Rb=Re=Rf=Rg=Rh=Rn=Ru=S=Sb=Sc=Se=Sg=Si=Sm=Sn=Sr=Ta=Tb=Tc=Te=Th=Ti=Tl=Tm=Ts=U=V=W=Xe=Y=Yb=Zn=Zr= index_label= index2_label= index_comment= index2_comment= CAS_number2= CAS_supplemental2= ATC_prefix2= ATC_suffix2= ATC_supplemental2= PubChem2= PubChemSubstance2= IUPHAR_ligand2= DrugBank2= ChemSpiderID2= UNII2= KEGG2= ChEBI2= ChEMBL2= PDB_ligand2= NIAID_ChemDB2= SMILES2= smiles2= StdInChI2= StdInChIKey2= CAS_number2_Ref= ChEBI2_Ref= ChEMBL2_Ref= ChemSpiderID2_Ref= DrugBank2_Ref= KEGG2_Ref= StdInChI2_Ref= StdInChIKey2_Ref= UNII2_Ref= QID= QID2= |cat=Chemical articles with unknown parameter in Infobox drug |format=0|errNS=0


@@@ (See parameter list). This message only shows in Preview, it will not show after you do Publish changes.

}}Expression error: Unrecognized punctuation character "{".Expression error: Unrecognized punctuation character "{".Expression error: Unrecognized punctuation character "{".

WikiDoc Resources for Bufexamac


Most recent articles on Bufexamac

Most cited articles on Bufexamac

Review articles on Bufexamac

Articles on Bufexamac in N Eng J Med, Lancet, BMJ


Powerpoint slides on Bufexamac

Images of Bufexamac

Photos of Bufexamac

Podcasts & MP3s on Bufexamac

Videos on Bufexamac

Evidence Based Medicine

Cochrane Collaboration on Bufexamac

Bandolier on Bufexamac

TRIP on Bufexamac

Clinical Trials

Ongoing Trials on Bufexamac at Clinical Trials.gov

Trial results on Bufexamac

Clinical Trials on Bufexamac at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bufexamac

NICE Guidance on Bufexamac


FDA on Bufexamac

CDC on Bufexamac


Books on Bufexamac


Bufexamac in the news

Be alerted to news on Bufexamac

News trends on Bufexamac


Blogs on Bufexamac


Definitions of Bufexamac

Patient Resources / Community

Patient resources on Bufexamac

Discussion groups on Bufexamac

Patient Handouts on Bufexamac

Directions to Hospitals Treating Bufexamac

Risk calculators and risk factors for Bufexamac

Healthcare Provider Resources

Symptoms of Bufexamac

Causes & Risk Factors for Bufexamac

Diagnostic studies for Bufexamac

Treatment of Bufexamac

Continuing Medical Education (CME)

CME Programs on Bufexamac


Bufexamac en Espanol

Bufexamac en Francais


Bufexamac in the Marketplace

Patents on Bufexamac

Experimental / Informatics

List of terms related to Bufexamac

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Bufexamac is a drug used as an anti-inflammatory agent on the skin, as well as rectally. Common brand names include Paraderm and Parfenac. It was withdrawn in Europe because of allergic reactions.


Ointments and lotions containing bufexamac are used for the treatment of subacute and chronic eczema of the skin, including atopic eczema, as well as sunburn and other minor burns,{{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= {{#invoke:Category handler|main}}{{#invoke:Category handler|main}}[citation needed] }} and itching. Suppositories containing bufexamac in combination with local anaesthetics are used against haemorrhoids.<ref name="Arzneistoff-Profile">{{#invoke:citation/CS1|citation |CitationClass=book }}</ref>


Bufexamac is thought to act by inhibiting the enzyme cyclooxygenase, which would make it a non-steroidal anti-inflammatory drug. Evidence on the mechanism of action is scarce.<ref>{{#invoke:citation/CS1|citation |CitationClass=book }}</ref> Furthermore, bufexamac was identified as a specific inhibitor of class IIB histone deacetylases (HDAC6 and HDAC10),<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> which may contribute to its clinical efficacy.{{ safesubst:#invoke:Unsubst||date=__DATE__ |$B= {{#invoke:Category handler|main}}{{#invoke:Category handler|main}}[citation needed] }}

Side effects

Bufexamac can cause severe contact dermatitis which is often hard to distinguish from the initial condition.<ref>{{#invoke:Citation/CS1|citation |CitationClass=journal }}</ref> As a consequence, the European Medicines Agency recommended to withdraw the marketing approval in April 2010.<ref>{{#invoke:citation/CS1|citation |CitationClass=news }}</ref>


<references group="" responsive="0"></references>

{{#invoke:Check for unknown parameters|check|unknown=|preview=Page using Template:Reflist with unknown parameter "_VALUE_"|ignoreblank=y| 1 | colwidth | group | liststyle | refs }}

{{#invoke:Navbox|navbox}} Template:Topical products for joint and muscular pain